The US Federal Drug Administration approves drug-maker Ranbaxy Laboratories to market and manufacture Ramipril, which is used in the treatment of cardiovascular diseases.
The pharmaceuticals company has received final nod from US Food and Drug Administration (US FDA) for Ramipril capsules, it said in a filing to the Bombay Stock Exchange.
"Ranbaxy is pleased to receive this final approval for Ramipril capsules. This is the third Abbreviated New Dug Application (ANDA) approval that materialized specific to Ohm Laboratories, in the last two months," Ranbaxy Pharmaceuticals Inc VP (Sales and Distribution) Jim Meehan said.
Ramipril is a bio-equivalent to King Pharmaceuticals' Altace drug, which can be used to treat hypertension.
The drug will be available in the strength of 5mg and 10mg capsules.
Ranbaxy's US-based subsidiary Ohm Laboratories' facility at New Jersey filed the application for the drug manufacturing permission.
Shares of Ranbaxy were trading at 139.70 rupees, down 1.13 percent on the Bombay Stock Exchange.